|
WO2002098445A1
(en)
*
|
2001-05-30 |
2002-12-12 |
Chugai Seiyaku Kabushiki Kaisha |
Protein preparation
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US8093357B2
(en)
|
2002-03-01 |
2012-01-10 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
FI20021761A0
(en)
*
|
2002-10-03 |
2002-10-03 |
Karyon Oy Ab Ltd |
New drugs and pharmaceuticals and their use
|
|
FI20021763A0
(en)
*
|
2002-10-03 |
2002-10-03 |
Karyon Oy Ab Ltd |
New therapeutically active substances and their use
|
|
FI20021760A0
(en)
*
|
2002-10-03 |
2002-10-03 |
Karyon Oy Ab Ltd |
New therapeutic / diagnostic substances and preparations and their applications
|
|
GB0230203D0
(en)
*
|
2002-12-27 |
2003-02-05 |
Domantis Ltd |
Fc fusion
|
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
JP5091476B2
(en)
*
|
2003-06-27 |
2012-12-05 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
Use of hydrophobic interaction chromatography or hinge region modification to generate homogeneous antibody solutions
|
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
|
WO2005063815A2
(en)
*
|
2003-11-12 |
2005-07-14 |
Biogen Idec Ma Inc. |
Fcϝ receptor-binding polypeptide variants and methods related thereto
|
|
EP2385069A3
(en)
|
2003-11-12 |
2012-05-30 |
Biogen Idec MA Inc. |
Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
|
|
EP1737890A2
(en)
|
2004-03-24 |
2007-01-03 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
|
US20150010550A1
(en)
|
2004-07-15 |
2015-01-08 |
Xencor, Inc. |
OPTIMIZED Fc VARIANTS
|
|
WO2006036834A2
(en)
|
2004-09-24 |
2006-04-06 |
Amgen Inc. |
MODIFIED Fc MOLECULES
|
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
AU2005304624B2
(en)
|
2004-11-12 |
2010-10-07 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
WO2006074399A2
(en)
*
|
2005-01-05 |
2006-07-13 |
Biogen Idec Ma Inc. |
Multispecific binding molecules comprising connecting peptides
|
|
SI1772465T1
(en)
|
2005-01-05 |
2009-06-30 |
F Star Biotech Forsch & Entw |
Synthetic immunoglobulin domains with modified binding properties in regions of the molecule that differ from the complementarity of the receiving regions
|
|
WO2007041635A2
(en)
|
2005-10-03 |
2007-04-12 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
|
US7973136B2
(en)
|
2005-10-06 |
2011-07-05 |
Xencor, Inc. |
Optimized anti-CD30 antibodies
|
|
CA2634083A1
(en)
*
|
2005-12-20 |
2007-06-28 |
Arana Therapeutics Limited |
Chimeric antibodies with part new world primate binding regions
|
|
AU2007211829C9
(en)
*
|
2006-02-01 |
2013-07-11 |
Cephalon Australia Pty Ltd |
Domain antibody construct
|
|
AT503889B1
(en)
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
MULTIVALENT IMMUNE LOBULINE
|
|
AT503902B1
(en)
*
|
2006-07-05 |
2008-06-15 |
F Star Biotech Forsch & Entw |
METHOD FOR MANIPULATING IMMUNE LOBULINS
|
|
US8524867B2
(en)
|
2006-08-14 |
2013-09-03 |
Xencor, Inc. |
Optimized antibodies that target CD19
|
|
AU2007299843B2
(en)
|
2006-09-18 |
2012-03-08 |
Xencor, Inc |
Optimized antibodies that target HM1.24
|
|
WO2009000006A1
(en)
|
2007-06-26 |
2008-12-31 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. |
Display of binding agents
|
|
WO2009062050A2
(en)
|
2007-11-08 |
2009-05-14 |
Neogenix Oncology, Inc. |
Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
|
|
DK2808343T3
(en)
|
2007-12-26 |
2019-08-19 |
Xencor Inc |
Fc variants with altered binding to FcRn
|
|
US12492253B1
(en)
|
2008-02-25 |
2025-12-09 |
Xencor, Inc. |
Anti-human C5 antibodies
|
|
EP2113255A1
(en)
|
2008-05-02 |
2009-11-04 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Cytotoxic immunoglobulin
|
|
AU2009334498A1
(en)
|
2008-12-31 |
2011-07-21 |
Biogen Idec Ma Inc. |
Anti-lymphotoxin antibodies
|
|
JP2013502458A
(en)
|
2009-08-24 |
2013-01-24 |
アムニクス オペレーティング インコーポレイテッド |
Coagulation factor VII composition and methods of making and using the same
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
EP2496691B1
(en)
|
2009-11-02 |
2017-02-22 |
University of Washington |
Therapeutic nuclease compositions and methods
|
|
WO2011091078A2
(en)
|
2010-01-19 |
2011-07-28 |
Xencor, Inc. |
Antibody fc variants with enhanced complement activity
|
|
PT2591006T
(en)
|
2010-07-09 |
2019-07-29 |
Bioverativ Therapeutics Inc |
Processable single chain molecules and polypeptides made using same
|
|
BR112013027547B1
(en)
|
2011-04-29 |
2021-01-19 |
University Of Washington |
polypeptide, dimer, composition, nucleic acid molecule, recombinant expression vector, microbial host cell, method for preparing the polypeptide and composition containing nucleasse
|
|
PL2717898T3
(en)
|
2011-06-10 |
2019-06-28 |
Bioverativ Therapeutics Inc. |
Pro-coagulant compounds and methods of use thereof
|
|
WO2013012733A1
(en)
|
2011-07-15 |
2013-01-24 |
Biogen Idec Ma Inc. |
Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
|
|
UY34317A
(en)
|
2011-09-12 |
2013-02-28 |
Genzyme Corp |
T cell antireceptor antibody (alpha) / ß
|
|
WO2013039954A1
(en)
|
2011-09-14 |
2013-03-21 |
Sanofi |
Anti-gitr antibodies
|
|
TWI640537B
(en)
|
2011-12-05 |
2018-11-11 |
Ｘ 染色體有限公司 |
PDGF receptor beta-binding polypeptide
|
|
KR102212098B1
(en)
|
2012-01-12 |
2021-02-03 |
바이오버라티브 테라퓨틱스 인크. |
Chimeric factor viii polypeptides and uses thereof
|
|
PT3564260T
(en)
|
2012-02-15 |
2023-01-18 |
Bioverativ Therapeutics Inc |
Factor viii compositions and methods of making and using same
|
|
CA2864126A1
(en)
|
2012-02-15 |
2013-08-22 |
Biogen Idec Ma Inc. |
Recombinant factor viii proteins
|
|
US9376494B2
(en)
|
2012-03-28 |
2016-06-28 |
Sanofi |
Antibodies to kallidin and des-Arg9-kallidin
|
|
SG11201407209YA
(en)
|
2012-05-07 |
2014-12-30 |
Sanofi Sa |
Methods for preventing biofilm formation
|
|
WO2013175276A1
(en)
|
2012-05-23 |
2013-11-28 |
Argen-X B.V |
Il-6 binding molecules
|
|
US10202595B2
(en)
|
2012-06-08 |
2019-02-12 |
Bioverativ Therapeutics Inc. |
Chimeric clotting factors
|
|
EP4079316A1
(en)
|
2012-06-08 |
2022-10-26 |
Bioverativ Therapeutics Inc. |
Procoagulant compounds
|
|
WO2014008480A2
(en)
|
2012-07-06 |
2014-01-09 |
Biogen Idec Ma Inc. |
Cell line expressing single chain factor viii polypeptides and uses thereof
|
|
PH12015500039B1
(en)
|
2012-07-11 |
2024-06-28 |
Bioverativ Therapeutics Inc |
Factor viii complex with xten and von willebrand factor protein, and uses thereof
|
|
US9790268B2
(en)
|
2012-09-12 |
2017-10-17 |
Genzyme Corporation |
Fc containing polypeptides with altered glycosylation and reduced effector function
|
|
DK3366705T5
(en)
|
2012-09-12 |
2024-09-30 |
Genzyme Corp |
FC-CONTAINING POLYPEPTIDES WITH ALTERED GLYCOSYRATION AND REDUCED EFFECTOR FUNCTION
|
|
DK2953972T3
(en)
|
2013-02-05 |
2020-10-12 |
Engmab Sarl |
PROCEDURE FOR SELECTING ANTIBODIES AGAINST BCMA
|
|
EP2762496A1
(en)
|
2013-02-05 |
2014-08-06 |
EngMab AG |
Method for the selection of antibodies against BCMA
|
|
DK3889173T5
(en)
|
2013-02-15 |
2024-08-05 |
Bioverativ Therapeutics Inc |
OPTIMIZED FACTOR VIII GENE
|
|
IL319584A
(en)
|
2013-03-11 |
2025-05-01 |
Genzyme Corp |
Hyperglycosylated binding polypeptides
|
|
WO2014144549A1
(en)
|
2013-03-15 |
2014-09-18 |
Biogen Idec Ma Inc. |
Factor ix polypeptide formulations
|
|
EP2789630A1
(en)
|
2013-04-09 |
2014-10-15 |
EngMab AG |
Bispecific antibodies against CD3e and ROR1
|
|
US10947269B2
(en)
|
2013-08-08 |
2021-03-16 |
Bioverativ Therapeutics Inc. |
Purification of chimeric FVIII molecules
|
|
KR20160035077A
(en)
|
2013-08-13 |
2016-03-30 |
사노피 |
Antibodies to plasminogen activator inhibitor-1(pai-1) and uses thereof
|
|
TW201734054A
(en)
|
2013-08-13 |
2017-10-01 |
賽諾菲公司 |
Antibody to plasminogen activin inhibitor-1 (PAI-1) and use thereof
|
|
TWI667255B
(en)
|
2013-08-14 |
2019-08-01 |
美商生物化學醫療公司 |
Factor viii-xten fusions and uses thereof
|
|
HUE057005T2
(en)
|
2013-09-25 |
2022-04-28 |
Bioverativ Therapeutics Inc |
Column virus inactivation procedures
|
|
SI3063275T1
(en)
|
2013-10-31 |
2020-02-28 |
Resolve Therapeutics, Llc |
Therapeutic nuclease-albumin fusions and methods
|
|
WO2015070014A1
(en)
|
2013-11-08 |
2015-05-14 |
Biogen Idec Ma Inc. |
Procoagulant fusion compound
|
|
EP3091997B1
(en)
|
2014-01-10 |
2022-07-06 |
Bioverativ Therapeutics Inc. |
Factor viii chimeric proteins and uses thereof
|
|
RS64072B1
(en)
|
2014-03-19 |
2023-04-28 |
Genzyme Corp |
Site-specific glycoengineering of targeting moieties
|
|
CN106164094B
(en)
|
2014-03-21 |
2021-05-14 |
X博迪公司 |
bispecific antigen-binding polypeptide
|
|
US11008561B2
(en)
|
2014-06-30 |
2021-05-18 |
Bioverativ Therapeutics Inc. |
Optimized factor IX gene
|
|
MX2017003897A
(en)
|
2014-09-26 |
2017-06-28 |
Bayer Pharma AG |
Stabilized adrenomedullin derivatives and use thereof.
|
|
US10064952B2
(en)
|
2014-10-09 |
2018-09-04 |
Genzyme Corporation |
Glycoengineered antibody drug conjugates
|
|
AU2015329965A1
(en)
|
2014-10-09 |
2017-04-27 |
Engmab Sàrl |
Bispecific antibodies against CD3epsilon and ROR1
|
|
DK3207130T3
(en)
|
2014-10-14 |
2019-11-11 |
Halozyme Inc |
Compositions of Adenosine Deaminase-2 (ADA2), Variants thereof, and Methods for Using the Same
|
|
JP7114460B2
(en)
|
2015-06-26 |
2022-08-08 |
サノフィ・バイオテクノロジー |
Monoclonal anti-IL-1RAcP antibody
|
|
LT3331910T
(en)
|
2015-08-03 |
2020-03-25 |
Engmab Sarl |
Monoclonal antibodies against human b cell maturation antigen (bcma)
|
|
EA201890423A1
(en)
|
2015-08-03 |
2018-07-31 |
Биовератив Терапьютикс Инк. |
SLIGHT PROTEINS OF THE FACTOR IX, METHODS OF THEIR RECEPTION AND APPLICATION
|
|
WO2017046746A1
(en)
|
2015-09-15 |
2017-03-23 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
|
|
AU2017214378B2
(en)
|
2016-02-01 |
2023-05-04 |
Bioverativ Therapeutics Inc. |
Optimized Factor VIII genes
|
|
CN109790526A
(en)
|
2016-07-01 |
2019-05-21 |
分解治疗有限责任公司 |
Optimized Dinuclease Fusions and Methods
|
|
TWI788307B
(en)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion
|
|
KR102687833B1
(en)
|
2016-11-02 |
2024-07-24 |
브리스톨-마이어스 스큅 컴퍼니 |
Combination use of dual specific antibodies and immunological drugs against BCMA and CD3 for the treatment of multiple myeloma
|
|
JP7748175B2
(en)
|
2016-12-02 |
2025-10-02 |
バイオベラティブ セラピューティクス インコーポレイテッド |
Methods for treating hemophilic arthropathy using chimeric clotting factors - Patent Application 20070122999
|
|
EP3548063A1
(en)
|
2016-12-02 |
2019-10-09 |
Bioverativ Therapeutics Inc. |
Methods of inducing immune tolerance to clotting factors
|
|
US11357841B2
(en)
|
2017-01-06 |
2022-06-14 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
|
|
AU2018205234B2
(en)
|
2017-01-06 |
2024-09-19 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (TILs) with tumor necrosis factor receptor superfamily (TNFRSF) agonists and therapeutic combinations of TILs and TNFRSF agonists
|
|
TW202409272A
(en)
|
2017-05-10 |
2024-03-01 |
美商艾歐凡斯生物治療公司 |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
BR112020002394A2
(en)
|
2017-08-09 |
2020-07-28 |
Bioverativ Therapeutics Inc. |
nucleic acid molecules and uses thereof
|
|
KR102777015B1
(en)
|
2017-08-22 |
2025-03-10 |
사나바이오, 엘엘씨 |
Availability of interferon receptors and their uses
|
|
CA3083118A1
(en)
|
2017-11-22 |
2019-05-31 |
Iovance Biotherapeutics, Inc. |
Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
|
|
EP3724885A2
(en)
|
2017-12-15 |
2020-10-21 |
Iovance Biotherapeutics, Inc. |
Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
|
|
WO2019152692A1
(en)
|
2018-02-01 |
2019-08-08 |
Bioverativ Therapeutics, Inc. |
Use of lentiviral vectors expressing factor viii
|
|
MA51875A
(en)
|
2018-02-13 |
2020-12-23 |
Iovance Biotherapeutics Inc |
TUMOR-INFILTRATING LYMPHOCYTES (TIL) EXPANSION WITH A2A ADENOSINE RECEPTOR ANTAGONISTS AND THERAPEUTIC COMBINATIONS OF TIL AND ADENOSINE A2A RECEPTOR ANTAGONISTS
|
|
CN112154153B
(en)
|
2018-03-28 |
2025-05-23 |
百时美施贵宝公司 |
Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
|
|
AU2019266042B2
(en)
*
|
2018-05-10 |
2025-08-07 |
Mirabiologics Inc. |
Artificial protein containing an antibody antigen-binding region, fused with bioactive peptides
|
|
CN112512555A
(en)
|
2018-05-18 |
2021-03-16 |
比奥维拉迪维治疗股份有限公司 |
How to treat hemophilia A
|
|
KR102848349B1
(en)
|
2018-06-04 |
2025-08-21 |
바이오젠 엠에이 인코포레이티드 |
Anti-VLA-4 antibodies with reduced effector function
|
|
MX2021000016A
(en)
|
2018-07-03 |
2021-03-09 |
Bristol Myers Squibb Co |
Fgf21 formulations.
|
|
JP7602454B2
(en)
|
2018-08-09 |
2024-12-18 |
バイオベラティブ セラピューティクス インコーポレイテッド |
Nucleic Acid Molecules and Their Use for Non-Viral Gene Therapy - Patent application
|
|
TW202031273A
(en)
|
2018-08-31 |
2020-09-01 |
美商艾歐凡斯生物治療公司 |
Treatment of nsclc patients refractory for anti-pd-1 antibody
|
|
WO2020096989A1
(en)
|
2018-11-05 |
2020-05-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients refractory for anti-pd-1 antibody
|
|
US12016885B2
(en)
|
2018-11-06 |
2024-06-25 |
Alsatech, Inc. |
Method of solubilizing TDP-43 protein aggregates in amyotrophic lateral sclerosis using a microvascular endothelial cell expressing an anti-TDP-43 Fab
|
|
BR112021013096A2
(en)
|
2019-01-04 |
2022-04-19 |
Resolve Therapeutics, Llc |
TREATMENT OF SJÖGREN'S DISEASE WITH NUCLEASE FUSION PROTEINS
|
|
BR112021016875A2
(en)
|
2019-03-01 |
2022-01-04 |
Iovance Biotherapeutics Inc |
Process for expansion of peripheral blood lymphocytes
|
|
CN113939534B
(en)
|
2019-04-03 |
2025-02-28 |
建新公司 |
Anti-αβTCR binding polypeptides with reduced fragmentation
|
|
SG11202110610VA
(en)
|
2019-04-09 |
2021-10-28 |
Abcuro Inc |
Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies
|
|
CN114174326A
(en)
|
2019-06-18 |
2022-03-11 |
拜耳公司 |
Long-term stable adrenomedullin analogues and uses thereof
|
|
TW202126284A
(en)
|
2019-09-30 |
2021-07-16 |
美商百歐維拉提夫治療公司 |
Lentiviral vector formulations
|
|
WO2021158938A1
(en)
|
2020-02-06 |
2021-08-12 |
Bristol-Myers Squibb Company |
Il-10 and uses thereof
|
|
US11879004B2
(en)
|
2020-02-28 |
2024-01-23 |
Genzyme Corporation |
Modified binding polypeptides for optimized drug conjugation
|
|
KR20230074703A
(en)
|
2020-06-24 |
2023-05-31 |
바이오버라티브 테라퓨틱스 인크. |
Method for removing free factor VIII from preparations of lentiviral vectors modified to express the protein
|
|
US20230355722A1
(en)
|
2020-06-29 |
2023-11-09 |
Resolve Therapeutics, Llc |
Treatment of sjogren’s syndrome with nuclease fusion proteins
|
|
EP4225330A1
(en)
|
2020-10-06 |
2023-08-16 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
US20240131064A1
(en)
|
2020-12-11 |
2024-04-25 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
|
|
EP4262811A1
(en)
|
2020-12-17 |
2023-10-25 |
Iovance Biotherapeutics, Inc. |
Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
|
|
CA3202473A1
(en)
|
2020-12-17 |
2022-06-23 |
Friedrich Graf Finckenstein |
Treatment of cancers with tumor infiltrating lymphocytes
|
|
WO2022147196A2
(en)
|
2020-12-31 |
2022-07-07 |
Iovance Biotherapeutics, Inc. |
Devices and processes for automated production of tumor infiltrating lymphocytes
|
|
TW202241508A
(en)
|
2021-01-29 |
2022-11-01 |
美商艾歐凡斯生物治療公司 |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
|
WO2022187741A2
(en)
|
2021-03-05 |
2022-09-09 |
Iovance Biotherapeutics, Inc. |
Tumor storage and cell culture compositions
|
|
US20240191191A1
(en)
|
2021-03-19 |
2024-06-13 |
Iovance Biotherapeutics, Inc. |
Methods for infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils
|
|
WO2022204155A1
(en)
|
2021-03-23 |
2022-09-29 |
Iovance Biotherapeutics, Inc. |
Cish gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
US20220313806A1
(en)
|
2021-03-25 |
2022-10-06 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for t-cell coculture potency assays and use with cell therapy products
|
|
WO2022212836A1
(en)
|
2021-04-01 |
2022-10-06 |
Pyxis Oncology, Inc. |
Gpnmb antibodies and methods of use
|
|
TW202308669A
(en)
|
2021-04-19 |
2023-03-01 |
美商艾歐凡斯生物治療公司 |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
|
CA3219148A1
(en)
|
2021-05-17 |
2022-11-24 |
Frederick G. Vogt |
Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
US20240365776A1
(en)
|
2021-07-22 |
2024-11-07 |
Iovance Biotherapeutics, Inc |
Method for cryopreservation of solid tumor fragments
|
|
US20250101112A1
(en)
|
2021-07-26 |
2025-03-27 |
Abcuro, Inc. |
Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies
|
|
EP4377446A1
(en)
|
2021-07-28 |
2024-06-05 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
|
|
CA3231018A1
(en)
|
2021-09-09 |
2023-03-16 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products using pd-1 talen knockdown
|
|
WO2023049862A1
(en)
|
2021-09-24 |
2023-03-30 |
Iovance Biotherapeutics, Inc. |
Expansion processes and agents for tumor infiltrating lymphocytes
|
|
CA3235824A1
(en)
|
2021-10-27 |
2023-05-04 |
Frederick G. Vogt |
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
|
|
AU2022388729A1
(en)
|
2021-11-10 |
2024-05-16 |
Iovance Biotherapeutics, Inc. |
Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
|
|
CA3243419A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
|
US20250101380A1
(en)
|
2022-01-28 |
2025-03-27 |
Iovance Biotherapeutics, Inc. |
Tumor infiltrating lymphocytes engineered to express payloads
|
|
CA3247638A1
(en)
|
2022-04-06 |
2023-10-12 |
Maria Fardis |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
JP2025512401A
(en)
|
2022-04-15 |
2025-04-17 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
TIL Expansion Process Using Specific Cytokine Combinations and/or AKTi Treatment
|
|
US20250281537A1
(en)
|
2022-05-10 |
2025-09-11 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
|
|
WO2024011114A1
(en)
|
2022-07-06 |
2024-01-11 |
Iovance Biotherapeutics, Inc. |
Devices and processes for automated production of tumor infiltrating lymphocytes
|
|
US20260021181A1
(en)
|
2022-08-01 |
2026-01-22 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
|
AU2023345467A1
(en)
|
2022-09-21 |
2025-05-08 |
Sanofi Biotechnology |
Humanized anti-il-1r3 antibody and methods of use
|
|
TW202432574A
(en)
|
2022-10-25 |
2024-08-16 |
比利時商艾伯霖克斯公司 |
GLYCOENGINEERED Fc VARIANT POLYPEPTIDES WITH ENHANCED EFFECTOR FUNCTION
|
|
WO2024098024A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
JP2025537155A
(en)
|
2022-11-04 |
2025-11-14 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
Methods for tumor infiltrating lymphocyte (TIL) expansion in conjunction with CD39/CD103 selection - Patent Application 20070122997
|
|
WO2024112571A2
(en)
|
2022-11-21 |
2024-05-30 |
Iovance Biotherapeutics, Inc. |
Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
|
|
JP2025539712A
(en)
|
2022-11-21 |
2025-12-09 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
Methods for assessing the proliferative potential of gene-edited T cells
|
|
WO2024151885A1
(en)
|
2023-01-13 |
2024-07-18 |
Iovance Biotherapeutics, Inc. |
Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
|
|
AU2024296516A1
(en)
|
2023-07-13 |
2026-01-22 |
Iovance Biotherapeutics, Inc. |
Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes
|
|
WO2025019790A1
(en)
|
2023-07-19 |
2025-01-23 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with trop-2 targeting adc
|
|
WO2025041077A1
(en)
|
2023-08-23 |
2025-02-27 |
Sanofi |
Ctla-4-based lysosomal degraders and uses thereof
|
|
WO2025101484A1
(en)
|
2023-11-06 |
2025-05-15 |
Iovance Biotherapeutics, Inc. |
Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
|
|
WO2025147544A1
(en)
|
2024-01-02 |
2025-07-10 |
Abcuro, Inc. |
Methods of treating inclusion body myositis (ibm)
|
|
WO2025147696A1
(en)
|
2024-01-05 |
2025-07-10 |
Resolve Therapeutics, Llc |
Treatment of symptoms associated with sars-cov viral infection or a prior sars-cov viral infection with nuclease agents
|
|
WO2025171182A1
(en)
|
2024-02-08 |
2025-08-14 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with cancer vaccine
|
|
WO2026006784A1
(en)
|
2024-06-28 |
2026-01-02 |
Iovance Biotherapeutics, Inc. |
Methods of making tumor reactive peripheral blood lymphocytes (trpbl)
|